Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/6293
Title: | Safety of daily low-dose aspirin use during pregnancy in low-income and middle-income countries |
Authors: | Short, Vanessa L Hoffman, Matthew Metgud, Mrityunjay Kavi, Avinash Goudar, Shivaprasad S Okitawutshu, Jean Tshefu, Antoinette Bose, Carl L Mwenechany, Musaku Chomba, Elwyn Carlo, Waldemar A Figueroa, Lester Garces, Ana Krebs, Nancy F Jessani, Saleem Saleem, Sarah Goldenberg, Robert L Kumar Das, Prabir Patel, Archana Hibberd, Patricia L Achieng, Emmah Nyongesa, Paul Esamai, Fabian Bucher, Sherri Nowak, Kayla J Goco, Norman Nolen, Tracy L McClure, Elizabeth M Koso-Thomas, Marion Miodovnik, Menachem Derman, Richard J |
Keywords: | Low- and middle-income countries Low-dose aspirin Potential side effects Pregnancy Preterm birth Unexpected emergency medical |
Issue Date: | Feb-2012 |
Publisher: | Elsevier |
Abstract: | BACKGROUND: The daily use of low-dose aspirin may be a safe, widely available, and inexpensive intervention for reducing the risk of pre term birth. Data on the potential side effects of low-dose aspirin use during pregnancy in low- and middle-income countries are needed. OBJECTIVE: This study aimed to assess differences in unexpected emergency medical visits and potential maternal side effects from a ran domized, double-blind, multicountry, placebo-controlled trial of low-dose aspirin use (81 mg daily, from 6 to 36 weeks’ gestation). STUDY DESIGN: This study was a secondary analysis of data from the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial, a trial of the Global Network for Women’s and Children’s Health conducted in India (2 sites), Pakistan, Guatemala, Democratic Republic of the Congo, Kenya, and Zambia. The outcomes for this analysis were unexpected emergency medical visits and the occurrence of the following potential side effects—overall and separately—nausea, vomiting, rash or hives, diarrhea, gastritis, vaginal bleeding, allergic reaction, and any other potential side effects. Analyses were performed overall and by geographic region. RESULTS: Between the aspirin (n=5943) and placebo (n=5936) study groups, there was no statistically significant difference in the risk of unexpected emergency medical visits or the risk of any potential side effect (overall). Of the 8 potential side effects assessed, only 1 (rash or hives) presented a different risk by treatment group (4.2% in the aspirin group vs 3.5% in the placebo group; relative risk, 1.20; 95% confidence interval, 1.01−1.43; P=.042). CONCLUSION: The daily use of low-dose aspirin seems to be a safe intervention for reducing the risk of preterm birth and well tolerated by nulliparous pregnant women between 6 and 36 weeks’ gestation in low- and middle-income countries. |
URI: | http://dx.doi.org/10.1016/j.xagr.2021.100003 http://ir.mu.ac.ke:8080/jspui/handle/123456789/6293 |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.